Last updated on February 2016

A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH). Clinical trial NCT02326454, MR901.


Brief description of study

A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH). Clinical trial NCT02326454, MR901.

Detailed Study Description

This study investigates the safety and efficacy of a photosensitive drug (talaporfin sodium) activated by an intraurethrally placed drug-activating device. Two different light doses will be tested against placebo groups in this 4-arm study.

Clinical Study Identifier: TX5594

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Cheryl Zinar, RN, BSN

Urologic Consultants of Southeastern Pennsylvania
Bala Cynwyd, PA USA
  Connect »